AACR: Personalized Vaccine for Cancer Tolerated, Feasible
Vaccine well tolerated in 13 patients; vaccine showed potential benefit in patients with solid tumors, multiple myeloma in phase 1 trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.